Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced it has entered into an agreement to sell its Fitzgerald Industries life sciences supply business, consisting of Benen Trading Ltd and Fitzgerald Industries International, Inc, to Biosynth for cash proceeds of approximately $30 million subject to customary adjustments. Biosynth is owned, amongst others, by KKR, Ampersand Capital Partners and management.
Read the full article: Trinity Biotech Announces the $30M Sale of Its Life Sciences Supply Business to Biosynth //
Source: https://www.globenewswire.com/news-release/2023/04/20/2651004/8624/en/Trinity-Biotech-Announces-the-30-Million-Sale-of-its-Life-Sciences-Supply-Business-to-Biosynth.html